Cidara Provides Corporate Update and Reports First Quarter 2019 Financial Results
09 mai 2019 16h13 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, May 09, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
Cidara Therapeutics to Present at the 18th Annual Needham Healthcare Conference
03 avr. 2019 16h04 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, April 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that...
Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2018 Financial Results
28 févr. 2019 16h24 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
Novan Phase 2 Molluscum Contagiosum Trial Achieves Statistical Significance in Preliminary Top Line Results
14 nov. 2018 06h30 HE
|
Novan, Inc.
Higher rates of complete clearance of all molluscum lesions at Week 12 for the two highest doses, SB206 8% and 12% twice-daily, more than double the rate observed in the vehicle groupClear treatment...
Novan Publication Supports Women’s Health Business Unit Initiative and Nitric Oxide’s Potential Against HPV-Associated Diseases
01 nov. 2018 08h05 HE
|
Novan, Inc.
Data from SB206 Phase 2 clinical trial in external genital warts have been published in the Journal of Drugs in DermatologySB206 was efficacious and well tolerated in the trialAdvancement of the late...
Novan Creates Dedicated Women’s Health Business Unit
25 oct. 2018 07h05 HE
|
Novan, Inc.
Business unit will focus on Novan’s proprietary nitric oxide technology and its application to target high-risk human papillomavirus (HPV) and associated cancers affecting women such as cervical...
Novan Expands Nitric Oxide Dermatology Business Partnership with Sato in Japan
08 oct. 2018 08h00 HE
|
Novan, Inc.
Expanded license agreement adds SB206 for the treatment of viral skin infections Novan to receive upfront cash consideration of approximately 1.25 billion JPY (~$11.0 million), payable over the next...
Novan’s Phase 2 Molluscum Contagiosum Trial Fully Enrolled: Top Line Results Targeted in November
01 oct. 2018 08h05 HE
|
Novan, Inc.
Trial enrollment completed meaningfully ahead of scheduleTop line results targeted to be communicated no later than mid-NovemberFavorable and consistent safety profile of SB206 enabled escalation to...
Cidara Provides Corporate Update and Reports Second Quarter 2018 Financial Results
08 août 2018 16h30 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
Cidara Provides Corporate Update and Reports First Quarter 2018 Financial Results
10 mai 2018 16h05 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...